The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy
- PMID: 31018108
- DOI: 10.1146/annurev-genom-083118-014933
The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy
Abstract
Facioscapulohumeral muscular dystrophy (FSHD), a progressive myopathy that afflicts individuals of all ages, provides a powerful model of the complex interplay between genetic and epigenetic mechanisms of chromatin regulation. FSHD is caused by dysregulation of a macrosatellite repeat, either by contraction of the repeat or by mutations in silencing proteins. Both cases lead to chromatin relaxation and, in the context of a permissive allele, aberrant expression of the DUX4 gene in skeletal muscle. DUX4 is a pioneer transcription factor that activates a program of gene expression during early human development, after which its expression is silenced in most somatic cells. When misexpressed in FSHD skeletal muscle, the DUX4 program leads to accumulated muscle pathology. Epigenetic regulators of the disease locus represent particularly attractive therapeutic targets for FSHD, as many are not global modifiers of the genome, and altering their expression or activity should allow correction of the underlying defect.
Keywords: DUX4; FSHD; chromatin; epigenetics; facioscapulohumeral muscular dystrophy; muscular dystrophy; skeletal muscle.
Similar articles
-
A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4.Hum Mol Genet. 2018 Dec 1;27(23):4024-4035. doi: 10.1093/hmg/ddy293. Hum Mol Genet. 2018. PMID: 30107443 Free PMC article.
-
Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.Clin Genet. 2020 Jun;97(6):799-814. doi: 10.1111/cge.13726. Epub 2020 Mar 4. Clin Genet. 2020. PMID: 32086799 Free PMC article. Review.
-
Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing.J Med Genet. 2019 Dec;56(12):828-837. doi: 10.1136/jmedgenet-2019-106402. Epub 2019 Nov 1. J Med Genet. 2019. PMID: 31676591 Free PMC article.
-
Facioscapulohumeral Muscular Dystrophy.Compr Physiol. 2017 Sep 12;7(4):1229-1279. doi: 10.1002/cphy.c160039. Compr Physiol. 2017. PMID: 28915324 Review.
-
Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy.Hum Mol Genet. 2015 Oct 15;24(R1):R17-23. doi: 10.1093/hmg/ddv237. Epub 2015 Jun 25. Hum Mol Genet. 2015. PMID: 26113644 Review.
Cited by
-
Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy.Front Pharmacol. 2021 Mar 12;12:642858. doi: 10.3389/fphar.2021.642858. eCollection 2021. Front Pharmacol. 2021. PMID: 33776777 Free PMC article. Review.
-
Downstream events initiated by expression of FSHD-associated DUX4: Studies of nucleocytoplasmic transport, γH2AX accumulation, and Bax/Bak-dependence.Biol Open. 2022 Feb 15;11(2):bio059145. doi: 10.1242/bio.059145. Epub 2022 Feb 22. Biol Open. 2022. PMID: 35191484 Free PMC article.
-
WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy.Nucleic Acids Res. 2023 Jun 9;51(10):5144-5161. doi: 10.1093/nar/gkad230. Nucleic Acids Res. 2023. PMID: 37021550 Free PMC article.
-
Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD.Mol Ther Methods Clin Dev. 2020 Dec 10;20:298-311. doi: 10.1016/j.omtm.2020.12.001. eCollection 2021 Mar 12. Mol Ther Methods Clin Dev. 2020. PMID: 33511244 Free PMC article.
-
Update on the Molecular Aspects and Methods Underlying the Complex Architecture of FSHD.Cells. 2022 Aug 29;11(17):2687. doi: 10.3390/cells11172687. Cells. 2022. PMID: 36078093 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
